Overview

A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers

Status:
Completed

Trial end date:
2004-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and galantamine tablet.

Phase:

Phase 1

Details

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Galantamine
Pharmaceutical Solutions